OGN - Organon projects in-line guidance for 2022 as topline and bottom-line contract

Organon (NYSE:OGN) set its 2022 revenue in line with Wall Street forecasts even as the contraction in its topline and the bottom line continued for another quarter in Q4 2021. The revenue for the quarter dropped ~1% YoY to $1.6B as Established Brands generated $1.0B in revenue with a ~2% YoY decline. Meanwhile, Women’s Health and Biosimilars reported $415M and $118M in revenue with ~6% and ~15% YoY growth, respectively. Full-year revenue dropped ~3% YoY to $6.3B as Established Brands and Women’s Health reported $4.0B and $1.6B revenue with ~10% YoY decline and ~4% YoY growth, respectively. Quarterly revenue from the U.S. climbed ~2% YoY to $347M, while Europe and Canada generated $427M revenue with a decline of ~3% YoY. Amid a ~11% YoY growth in SG&A expenses, the net income for the quarter dropped ~45% YoY to $202M even as gross margin for Q4 2021improved to ~63% from ~62%

For further details see:

Organon projects in-line guidance for 2022 as topline and bottom-line contract